AzTrials
AzTrials

CataractNCT03921762

Comparison of a New EDOF-IOL With a Standard-EDOF-IOL

A study testing Cataract surgery with Artis Active IOLs and Cataract surgery with AT Lara IOLs in people with Cataract, run by Prim. Prof. Dr. Oliver Findl, MBA at 1 site in Austria.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Comparison of the new extended depth of focus (EDOF) intraocular lens (IOL) ARTIS ACTIVE, which is designed as a twinset of IOLs, with the standard EDOF IOL AT Lara . Read more about this study

Who is it for?
Ages 50 to 105 yearsHealthy volunteers can take part
Conditions the study is for
Cataract
What is being tested?
Cataract surgery with Artis Active IOLs and Cataract surgery with AT Lara IOLs
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
1 siteAustria
Study dates
29 Oct 2018to 1 Oct 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 105 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • > 50 years old
  • Bilateral age-related cataract
  • Qualify for bilateral implantation within 1 month
  • No previous refractive or ocular surgery
  • Available IOL dioptre range: 18 to 27D
  • Expected postoperative astigmatism ≤ 0.75D

Who cannot join

  • Pupil > 4 mm
  • Occupation requiring night-time driving or any occupation incompatible with multifocality
  • Acute or chronic disease or illness that would increase risk or confound study results [e.g. diabetes mellitus (with retinopathy), immunocompromised, glaucoma, epiretinal membrane, cornea guttata, etc….] found to be relevant by the investigators
  • Amblyopia, strabismus
  • Extremely shallow anterior chamber
  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, uveitis, Marfan's syndrome)
Show all 9Show fewer
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/ scotopic conditions)
  • Instability to place the intraocular lens safely at the location planned
  • Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)

Trial locations and contacts

1 site in 1 country.

Hannah Zwickl, MD contact

+43 1 91021/57564

office@viros.at

Manuel Ruiss, MSc. contact

+43 1 91021/57564

office@viros.at

Austria1 site, 1 recruiting
  • Vienna Institute for Research in Ocular Surgery (VIROS)

    Vienna, 1140

    Hannah Zwickl, MD, +43 1 91021/57564, office@viros.at

    Manuel Ruiss, MSc., +43 1 91021/57564, office@viros.at

    Recruiting

Other trials in Austria

About this study

Official title: Comparison of Visual Outcomes After Bilateral Implantation of a New Extended Depth of Focus (EDOF) IOL Twinset With Bilateral Standard EDOF IOLs

Comparison of the new extended depth of focus (EDOF) intraocular lens (IOL) ARTIS ACTIVE, which is designed as a twinset of IOLs, with the standard EDOF IOL AT Lara .

Read the detailed description

Spectacle independence is a central aim in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia or low myopia, leads to high levels of patient satisfaction in distance vision, spectacle dependence for reading and other near vision tasks is the usual result.

The option commonly used to achieve spectacle independence are multifocal intraocular lenses (IOLs). Multifocal IOLs either use a refractive or diffractive design or a combination of both or segmented asymmetric optics. The principal of the refractive design is based on changing the route of light rays by thickness, curvature and optical density of the lens. The principal of diffractive design is based on scattering of light rays when passing an edge in the material of the lens. Usually, the characteristic diffractive ring patterns are incorporated on the posterior surface of an IOL, whereas the anterior lens surface remains purely refractive. One potentially negative aspect of multifocal refractive IOLs is pupil size dependence, another is loss of light energy to higher order diffraction which is not useful for the patient. In clinical studies, diffractive lenses resulted in a better outcome in terms of optical quality, better contrast sensitivity, and less photic phenomena (dysphotopsia such as halos and glare) compared to refractive lenses.

Until recently multifocal lenses were typically bifocal with a focus assigned to near and a focus assigned to far vision. However, the intermediate working distance is poorly covered by the bifocal design. Since objects commonly viewed in this distance include computer displays and tablets, the intermediate distance has become a crucial part in daily life. Variations in the addition of power chosen for near vision provided some intermediate visual acuity, but still suboptimal. Therefore, a new concept of multifocality has been introduced, the trifocal lens. Trifocal IOLs provide three focal distances: far, intermediate, and near. This ideally results in even less spectacle dependence, including for computer work. However, one potential disadvantage of trifocal IOLs is slightly poorer near vision compared to bifocal IOLs with need for reading glasses for prolonged fine near work and loss of contrast sensitivity in the intermediate distance.

A better intermediate performance concerning contrast vision compared to trifocal IOLs can be reached using enhanced depth of focus (EDOF) lenses. These IOLs have an extended far focus area which reaches to the intermediate distance, providing high-quality vision over a continuous range of focus, rather than distinct foci with blur in between.

To provide similar outcomes to trifocal IOLs, mix-and-match of additions ("blended vision") is another option, in which additions of multifocal IOLs between both eyes differ. The idea behind it is to improve the contrast in the intermediate distance compared to trifocal IOLs. The combination of +1.75D/ +4D10 and +1.5D/ +3D11 successfully achieved a regular defocus curve, but patient's subjective binocular comfort was not determined. To preserve the binocular balance between the eyes, a difference in addition of 0.5D was proposed and the combination of +2.5D/ +3D showed similar results as trifocal IOLs, except in the intermediate range of -1D and -1.5D.

Therefore, it would be necessary to provide an IOL with a continuum of good visual acuity from distance to 40 cm using binocularity to preserve binocular balance between the eyes. Hence, the primary objective of this study is to compare a new designed twinset of EDOF IOLs, ARTIS ACTIVE (Artis Active Mid and Artis Active Plus), with the standard EDOF IOL AT Lara in binocular visual acuity at 40 cm. Secondary objective is to compare binocular contrast sensitivity (with and without glare), binocular defocus curves with distance correction, monocular and binocular halos, and reading speed between the two IOLs.

Conditions
Cataract
Being tested
Cataract surgery with Artis Active IOLs, Cataract surgery with AT Lara IOLs
Keywords
Cataract surgery, Enhanced depth of focus (EDOF), Intraocular lens
Medical subject headings
Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cataract surgery with Artis Active IOLsProcedure or surgery

    Patients will be implanted with the Artis Active IOLs during cataract surgery

  • Cataract surgery with AT Lara IOLsProcedure or surgery

    Patients will be implanted with the AT Lara IOLs during cataract surgery

Study groups in NCT03921762
Study groupRoleWhat they receive
Artis Active IOLExperimentalArtis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
Receives: Procedure: Cataract surgery with Artis Active IOLs
AT Lara IOLExperimentalAT Lara IOLs will be implanted in patients eyes during cataract surgery
Receives: Procedure: Cataract surgery with AT Lara IOLs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of binocular near visual acuity

    Binocular near visual acuity in logMar will be measured at 40 cm distance using an ETDRS visual acuity chart

    Measured: 12 months

Secondary outcomes (4)
  1. Assessment of binocular far and intermediate visual acuity

    Binocular far and intermediate visual acuity in logMar will be measured at 4 metre and 70 cm distance using an ETDRS visual acuity chart

    Measured: 12 months

  2. Assessment of halos

    Extent of halos will be measured and analysed using the Aston halometer

    Measured: 12 months

  3. Assessment of binocular contrast sensitivity

    Binocular contrast sensitivity will be measured using the Optec Vision tester under mesopic and photopic conditions

    Measured: 12 months

  4. Assessment of reading speed

    Patients reading speed will be measured using the Salzburg Reading Desk

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2019
  2. Study start29 Oct 2018
  3. Primary completion1 Apr 2020 (estimated)
  4. Study completion1 Oct 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03921762
Sponsor's protocol ID
Artis Active
Status last verified
Apr 2019
First submitted
17 Apr 2019
Last updated
19 Apr 2019
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Cataract surgery with Artis Active IOLs and Cataract surgery with AT Lara IOLs in people with Cataract, run by Prim. Prof. Dr. Oliver Findl, MBA at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hannah Zwickl, MD (+43 1 91021/57564, office@viros.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of binocular near visual acuity (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in